Filings Set For Takeda’s Ixazomib On Phase III Data
This article was originally published in PharmAsia News
Takeda is set to file for approval worldwide of its leading oral proteasome inhibitor ixazomib in multiple myeloma on the basis of encouraging interim data from the Phase III TOURMALINE-MM1 study.
You may also be interested in...
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.